RAET1L and cancer: Given this and the near-exclusive expression of ULBP6/2/5 on malignant cells in the tumor microenvironment, we hypothesized that leveraging the Fc domain of an anti-ULBP6/2/5 antibody to augment ADCC upon binding to ULBP6/2/5-expressing cancer cells may further enhance antitumor immunity.